Blood online
Home About Blood Authors Subscriptions Permission Advertising Public Access contact us
 

 
Advanced
Current Issue
First Edition
Archives
Submit to Blood
Search
American Society of Hematology
Meeting Abstracts
Email Alerts
 Blood, 1 September 2005, Vol. 106, No. 5, pp. 1839-1842.
Prepublished online as a Blood First Edition Paper on May 5, 2005; DOI 10.1182/blood-2005-01-0427.

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
2005-01-0427v1
106/5/1839    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Right arrow Rights and Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Böll, B.
Right arrow Articles by Pogge von Strandmann, E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Böll, B.
Right arrow Articles by Pogge von Strandmann, E.
Related Collections
Right arrow Immunotherapy
Right arrow Brief Reports
Right arrow Immunobiology
Right arrow Neoplasia
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

arrow to previous article Previous Article  |  Table of Contents  |  Next Article next article arrow

NEOPLASIA
Brief report

The fully human anti-CD30 antibody 5F11 activates NF-{kappa}B and sensitizes lymphoma cells to bortezomib-induced apoptosis

Boris Böll, Hinrich Hansen, Friederike Heuck, Katrin Reiners, Peter Borchmann, Achim Rothe, Andreas Engert, and Elke Pogge von Strandmann

From the Laboratory of Immunotherapy, Department I for Internal Medicine, University Hospital of Cologne, Germany.

5F11, a fully human monoclonal antibody directed against CD30, effectively induces killing of CD30-expressing lymphoma cell lines in vitro and in animal models. A recently conducted phase 1/2 study shows that 5F11 is well tolerated in heavily pretreated patients with relapsed and refractory CD30+ lymphoma and has some clinical activity. In the present study, we demonstrate that 5F11 activates nuclear factor {kappa}B (NF-{kappa}B) and the anti-apoptotic protein cellular FLICE (Fas-associating protein with death domain-like interleukin-1{beta}-converting enzyme) inhibitory protein (c-flip) in Hodgkin lymphoma (HD)-derived cell lines, which might cause apoptosis resistance, thus limiting the clinical use of 5F11. To overcome this resistance, we combined 5F11 with the proteasome inhibitor bortezomib, which has been shown to suppress NF-{kappa}B activity. This combination revealed a synergistic cytotoxic effect in vitro and in a human HD xenograft model provided that 5F11 precedes bortezomib treatment. We conclude that initial 5F11-mediated NF-{kappa}B signaling sensitizes the tumor cells to bortezomib-induced cell death. These data suggest a therapeutic value of this combination for HD patients. (Blood. 2005;106:1839-1842)


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
 Ann OncolHome page
J. H. Mendler, J. Kelly, S. Voci, D. Marquis, L. Rich, R. M. Rossi, S. H. Bernstein, C. T. Jordan, J. Liesveld, R. I. Fisher, et al.
Bortezomib and gemcitabine in relapsed or refractory Hodgkin's lymphoma
Ann. Onc., May 25, 2008; (2008) mdn365v1.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Pathol.Home page
B. Hirsch, M. Hummel, S. Bentink, F. Fouladi, R. Spang, R. Zollinger, H. Stein, and H. Durkop
CD30-Induced Signaling Is Absent in Hodgkin's Cells but Present in Anaplastic Large Cell Lymphoma Cells
Am. J. Pathol., February 1, 2008; 172(2): 510 - 520.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
S. M. Ansell, S. M. Horwitz, A. Engert, K. D. Khan, T. Lin, R. Strair, T. Keler, R. Graziano, D. Blanset, M. Yellin, et al.
Phase I/II Study of an Anti-CD30 Monoclonal Antibody (MDX-060) in Hodgkin's Lymphoma and Anaplastic Large-Cell Lymphoma
J. Clin. Oncol., July 1, 2007; 25(19): 2764 - 2769.
[Abstract] [Full Text] [PDF]

Home page
 haematolHome page
B. von Tresckow, E. P. von Strandmann, S. Sasse, S. Tawadros, A. Engert, and H. P. Hansen
Simvastatin-dependent apoptosis in Hodgkin's lymphoma cells and growth impairment of human Hodgkin's tumors in vivo
Haematologica, May 1, 2007; 92(5): 682 - 685.
[Abstract] [Full Text] [PDF]

Home page
 haematolHome page
S. Trelle, O. Sezer, R. Naumann, M. Rummel, U. Keller, A. Engert, and P. Borchmann
Bortezomib in combination with dexamethasone for patients with relapsed Hodgkin's lymphoma: results of a prematurely closed phase II study (NCT00148018)
Haematologica, April 1, 2007; 92(4): 568 - 569.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
J.-P. Armand, A. K. Burnett, J. Drach, J.-L. Harousseau, B. Lowenberg, and J. San Miguel
The Emerging Role of Targeted Therapy for Hematologic Malignancies: Update on Bortezomib and Tipifarnib
Oncologist, March 1, 2007; 12(3): 281 - 290.
[Abstract] [Full Text] [PDF]


click for free articles
home about blood authors subscriptions permissions advertising public access contact us
Sponsor: Genentech BioOncology and and Biogen Idec
Blood Online is supported in part by
Genentech BioOncology and Biogen Idec
  Copyright © 2005 by American Society of Hematology         Online ISSN: 1528-0020